Drug Trial Radar · NCT04956328
Study of Obeticholic Acid(OCA) Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)
Last checked: Nov 20, 2026Latest source record: Jul 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
120
Planned (sponsor's estimate)
Start
Jul 22, 2021
Primary completion
Sep 20, 2023
Study completion Sep 20, 2023
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Obecholic acid is a modified bile acid and Farnesoid X receptor (FXR) agonist. FXR is a key regulator of bile acid synthesis and transport. Bile acids are used by the body to help with digestion. Conventional therapy with obecholic acid will improve liver function of patients with PBC.
Conditions
- Primary Biliary Cirrhosis
Interventions
Obeticholic Acid TabletsDrug
Obeticholic Acid:Once a day (QD) by mouth (PO).
UDCADrug
UDCA:continue prestudy dose
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of PBC patients reaching the compound endpoint after 48 weeks of treatment (Compound endpoint: alkaline phosphatase (ALP) < 1.67× Upper Limit of Normal(ULN), ALP decrease by at least 15% , and total bilirubin ≤ ULN )Time frame: up to 48 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The first hospital of Jilin University
Changchun, Jilin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.